Volume Alert - PFE 30.05 Pfizer Inc $PFE Hit a high today of 30.17 Closing the day 10:30 at 30.05 -0.29 -0.96% With a day low of 29.88 and a total volume of 7,953,936.
PFE Recent Posts: http://investorshangout.com/Pfizer-PFE-52267/
PFE Pfizer Inc Recent Headline News
Early Glance: Pharmaceuticals companies
AP - 28 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.30 (+0.14), BAX: 71.54 (-0.21), PFE: 30.03 (-0.31), BMY: 58.20 (+0.25)
Watch for Shares of Pfizer (PFE) to Approach Support at $30.03
Comtex SmarTrend(R) - 47 mins ago
Pfizer (NYSE
FE) has opened bearishly below the pivot of $30.37 today and has reached the first level of support at $30.19. Should the shares continue to fall, the support pivots of $30.03 and $29.69 will be of interest.
PFE: 30.03 (-0.31)
Pfizer Strikes Immuno-oncology Pact with Merck After Abandoning AstraZeneca
at The Street - 53 mins ago
The transaction includes an upfront payment of $850 million to the German company, followed by up to $2 billion in milestone rewards.
PFE: 30.03 (-0.31), MRK: 59.79 (+0.72), AZN: 72.32 (-0.53)
Adexanet Alfa reverses anticoagulant effect of Eliquis in first stage of Phase 3
Seeking Alpha - at Seeking Alpha - 59 mins ago
PTLA: 26.91 (+0.34), PFE: 30.03 (-0.31), BMY: 58.20 (+0.25)
Earnings Look Back: Pfizer Is Up 4.3% Since Reporting Quarterly Results 2 Weeks Ago (PFE)
Comtex SmarTrend(R) - 1 hr 1 min ago
When Pfizer (NYSE FE) reported earnings two weeks ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $0.55 on sales of $12.3 billion. The company actually reported EPS of $0.57 on sales of $12.4 billion, beating EPS estimates by $0.02 and beating revenue estimates by $96.7 million. Since the company's report, shares of Pfizer have risen from $29.09 to $30.34, representing a gain of 4.3% in the past 20 days.
PFE: 30.03 (-0.31)
Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)
GlobeNewswire - 2 hrs 38 mins ago
-- Andexanet Alfa Rapidly Reversed the Anticoagulant Effect of the Factor Xa Inhibitor Eliquis (apixaban) Among All Study Participants --
PTLA: 26.91 (+0.34), PFE: 30.03 (-0.31), BMY: 58.20 (+0.25)
3 Stocks the Smartest Investors Are Buying Right Now
Motley Fool Staff - Motley Fool - Mon Nov 17, 6:51AM CST
Stocks have soared to new heights over the last few years. Does this mean there are no longer any good buys out there? According to three of our contributing writers, that's not the case. 1. Broad-market exchange-traded funds ( John Maxfield )...
VOO: 187.17 (-0.16), GILD: 101.05 (-1.01), PFE: 30.03 (-0.31)
Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 135.82 (+1.61), ACT: 253.26 (+9.49), F: 15.42 (+0.28), FB: 74.73 (-0.15), PFE: 30.03 (-0.31), AGN: 212.51 (+13.86), YHOO: 51.13 (-0.62), PBR: 9.55 (-0.40), DFS: 64.90 (-0.08), DTSI: 32.91 (-0.12), SPY: 204.10 (-0.14), LNKD: 225.07 (-8.82), QQQ: 102.88 (-0.34), AME: 51.17 (-0.53), MRK: 59.78 (+0.71), AOL: 46.08 (+0.04), AZN: 72.32 (-0.53), GM: 32.20 (+0.41), CVEO: 10.64 (unch), DD: 70.63 (-0.17)
European Stocks Follow Asia Lower as Japan Slips Into Recession
at The Street - Mon Nov 17, 4:59AM CST
European stocks backpedal on Monday, following Asia lower as Japan's economy unexpectedly fell into a recession.
PFE: 30.03 (-0.31)
Pfizer cuts profit outlook after Merck deal
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:06AM CST
AZN: 72.32 (-0.53), MRK: 59.78 (+0.71), PFE: 30.03 (-0.31)
Merck KGaA, Darmstadt, Germany, Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology
Business Wire - Mon Nov 17, 2:40AM CST
--Joint investment and combined strengths and capabilities will further maximize potential of Merck KGaA, Darmstadt, Germany,'s asset in the highly competitive anti-PD-1 / anti-PD-L1 space
PFE: 30.03 (-0.31)
Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology
Business Wire - Mon Nov 17, 1:53AM CST
--Up to 20 High Priority Immuno-Oncology Clinical Development Programs, Including Up to 6 Registration Trials, Expected to Commence in 2015
PFE: 30.03 (-0.31)
AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Nov 16, 9:20AM CST
Dividend stocks are powerful long-term investing vehicles that should be an integral part of a well balanced portfolio. Picking good dividend stocks, though, is another story altogether. High dividend yields may be an artificial by-product of a...
PFE: 30.03 (-0.31), AZN: 72.31 (-0.54), ABBV: 64.98 (+0.98)
Final Glance: Pharmaceuticals companies
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.30 (+0.14), BAX: 71.54 (-0.21), PFE: 30.03 (-0.31), BMY: 58.20 (+0.25)
Zoetis adopts shareholder rights plan
By The Associated Press - AP - Fri Nov 14, 4:47PM CST
Zoetis Inc. said Friday that it has adopted a one-year shareholder rights plan.
ZTS: 43.80 (+0.66), PFE: 30.03 (-0.31)
Midday Glance: Pharmaceuticals companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:
JNJ: 108.30 (+0.14), BAX: 71.54 (-0.21), PFE: 30.03 (-0.31), BMY: 58.20 (+0.25)
Is Johnson & Johnson A Stock Worth Having In The Portfolio Right Now?
Abba's Aces - at Seeking Alpha - Fri Nov 14, 1:36AM CST
JNJ: 108.30 (+0.14), PFE: 30.03 (-0.31), ABBV: 64.98 (+0.98)
Most active New York Stock Exchange-traded stocks
AP - Thu Nov 13, 5:05PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KMI: 39.98 (+0.61), ZTS: 43.80 (+0.66), GE: 26.63 (+0.17), F: 15.42 (+0.28), S: 5.01 (-0.04), PFE: 30.03 (-0.31), JCP: 7.29 (-0.09), HAL: 51.16 (-3.92), WMT: 83.11 (+0.15), BAC: 17.12 (-0.02), TWTR: 40.81 (-1.04), GNW: 9.35 (-0.06)
PFE Recent Posts: http://investorshangout.com/Pfizer-PFE-52267/
PFE Pfizer Inc Recent Headline News
Early Glance: Pharmaceuticals companies
AP - 28 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.30 (+0.14), BAX: 71.54 (-0.21), PFE: 30.03 (-0.31), BMY: 58.20 (+0.25)
Watch for Shares of Pfizer (PFE) to Approach Support at $30.03
Comtex SmarTrend(R) - 47 mins ago
Pfizer (NYSE
FE) has opened bearishly below the pivot of $30.37 today and has reached the first level of support at $30.19. Should the shares continue to fall, the support pivots of $30.03 and $29.69 will be of interest. PFE: 30.03 (-0.31)
Pfizer Strikes Immuno-oncology Pact with Merck After Abandoning AstraZeneca
at The Street - 53 mins ago
The transaction includes an upfront payment of $850 million to the German company, followed by up to $2 billion in milestone rewards.
PFE: 30.03 (-0.31), MRK: 59.79 (+0.72), AZN: 72.32 (-0.53)
Adexanet Alfa reverses anticoagulant effect of Eliquis in first stage of Phase 3
Seeking Alpha - at Seeking Alpha - 59 mins ago
PTLA: 26.91 (+0.34), PFE: 30.03 (-0.31), BMY: 58.20 (+0.25)
Earnings Look Back: Pfizer Is Up 4.3% Since Reporting Quarterly Results 2 Weeks Ago (PFE)
Comtex SmarTrend(R) - 1 hr 1 min ago
When Pfizer (NYSE
FE) reported earnings two weeks ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $0.55 on sales of $12.3 billion. The company actually reported EPS of $0.57 on sales of $12.4 billion, beating EPS estimates by $0.02 and beating revenue estimates by $96.7 million. Since the company's report, shares of Pfizer have risen from $29.09 to $30.34, representing a gain of 4.3% in the past 20 days. PFE: 30.03 (-0.31)
Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)
GlobeNewswire - 2 hrs 38 mins ago
-- Andexanet Alfa Rapidly Reversed the Anticoagulant Effect of the Factor Xa Inhibitor Eliquis (apixaban) Among All Study Participants --
PTLA: 26.91 (+0.34), PFE: 30.03 (-0.31), BMY: 58.20 (+0.25)
3 Stocks the Smartest Investors Are Buying Right Now
Motley Fool Staff - Motley Fool - Mon Nov 17, 6:51AM CST
Stocks have soared to new heights over the last few years. Does this mean there are no longer any good buys out there? According to three of our contributing writers, that's not the case. 1. Broad-market exchange-traded funds ( John Maxfield )...
VOO: 187.17 (-0.16), GILD: 101.05 (-1.01), PFE: 30.03 (-0.31)
Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 135.82 (+1.61), ACT: 253.26 (+9.49), F: 15.42 (+0.28), FB: 74.73 (-0.15), PFE: 30.03 (-0.31), AGN: 212.51 (+13.86), YHOO: 51.13 (-0.62), PBR: 9.55 (-0.40), DFS: 64.90 (-0.08), DTSI: 32.91 (-0.12), SPY: 204.10 (-0.14), LNKD: 225.07 (-8.82), QQQ: 102.88 (-0.34), AME: 51.17 (-0.53), MRK: 59.78 (+0.71), AOL: 46.08 (+0.04), AZN: 72.32 (-0.53), GM: 32.20 (+0.41), CVEO: 10.64 (unch), DD: 70.63 (-0.17)
European Stocks Follow Asia Lower as Japan Slips Into Recession
at The Street - Mon Nov 17, 4:59AM CST
European stocks backpedal on Monday, following Asia lower as Japan's economy unexpectedly fell into a recession.
PFE: 30.03 (-0.31)
Pfizer cuts profit outlook after Merck deal
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:06AM CST
AZN: 72.32 (-0.53), MRK: 59.78 (+0.71), PFE: 30.03 (-0.31)
Merck KGaA, Darmstadt, Germany, Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology
Business Wire - Mon Nov 17, 2:40AM CST
--Joint investment and combined strengths and capabilities will further maximize potential of Merck KGaA, Darmstadt, Germany,'s asset in the highly competitive anti-PD-1 / anti-PD-L1 space
PFE: 30.03 (-0.31)
Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology
Business Wire - Mon Nov 17, 1:53AM CST
--Up to 20 High Priority Immuno-Oncology Clinical Development Programs, Including Up to 6 Registration Trials, Expected to Commence in 2015
PFE: 30.03 (-0.31)
AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Nov 16, 9:20AM CST
Dividend stocks are powerful long-term investing vehicles that should be an integral part of a well balanced portfolio. Picking good dividend stocks, though, is another story altogether. High dividend yields may be an artificial by-product of a...
PFE: 30.03 (-0.31), AZN: 72.31 (-0.54), ABBV: 64.98 (+0.98)
Final Glance: Pharmaceuticals companies
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.30 (+0.14), BAX: 71.54 (-0.21), PFE: 30.03 (-0.31), BMY: 58.20 (+0.25)
Zoetis adopts shareholder rights plan
By The Associated Press - AP - Fri Nov 14, 4:47PM CST
Zoetis Inc. said Friday that it has adopted a one-year shareholder rights plan.
ZTS: 43.80 (+0.66), PFE: 30.03 (-0.31)
Midday Glance: Pharmaceuticals companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:
JNJ: 108.30 (+0.14), BAX: 71.54 (-0.21), PFE: 30.03 (-0.31), BMY: 58.20 (+0.25)
Is Johnson & Johnson A Stock Worth Having In The Portfolio Right Now?
Abba's Aces - at Seeking Alpha - Fri Nov 14, 1:36AM CST
JNJ: 108.30 (+0.14), PFE: 30.03 (-0.31), ABBV: 64.98 (+0.98)
Most active New York Stock Exchange-traded stocks
AP - Thu Nov 13, 5:05PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KMI: 39.98 (+0.61), ZTS: 43.80 (+0.66), GE: 26.63 (+0.17), F: 15.42 (+0.28), S: 5.01 (-0.04), PFE: 30.03 (-0.31), JCP: 7.29 (-0.09), HAL: 51.16 (-3.92), WMT: 83.11 (+0.15), BAC: 17.12 (-0.02), TWTR: 40.81 (-1.04), GNW: 9.35 (-0.06)
